摘要
Immunotherapy which has been in practice for more than 20 years proves effective for the treatment of metastatic renal cell carcinoma （mRCC）. Anti-angiogenesis-targeted therapy has recently been identified as a promising therapeutic strategy for mRCC. This study was aimed to evaluate the effectiveness of vascular endothelial growth factor （VEGF） pathway-targeted therapy for mRCC by comparing its effectiveness with that of immunotherapy. The electronic databases were searched. Randomized controlled trials （RCTs） on comparison of VEGF inhibiting drugs （sorafenib, sunitinib and bevacizumab） with interferon （IFN） or placebo for mRCC treatment were included. Data were pooled to meta-analyze. A total of 7 RCTs with 3451 patients were involved. The results showed that anti-VEGF agents improved progression-free survival （PFS） and offered substantial clinical benefits to patients with mRCC. Among them, sunitinib had a higher overall response rate （ORR） than IFN （47% versus 12%, P〈0.000001）. Bevacizumab plus IFN produced a superior PFS [risk ratio （RR）： 0.86, 95% confidence interval （CI）： 0.76-0.97; P=0.01] and ORR （RR： 2.19; 95% CI： 1.72-2.78; P〈0.00001） in patients with mRCC over IFN, but it yielded an increase by 31% in the risk of serious toxic effects （RR： 1.31; 95% CI 1.20-1.43; P〈0.00001） as compared with IFN. The overall survival （OS） was extended by sorafenib （17.8 months） and sunitinib （26.4 months） as compared with IFN （13 months）. It was concluded that compared with IFN therapy, VEGF pathway-targeted therapies improved PFS and achieved significant therapeutic benefits in mRCC. However, the risk to benefit ratio of these agents needs to be further evaluated.
Immunotherapy which has been in practice for more than 20 years proves effective for the treatment of metastatic renal cell carcinoma （mRCC）. Anti-angiogenesis-targeted therapy has recently been identified as a promising therapeutic strategy for mRCC. This study was aimed to evaluate the effectiveness of vascular endothelial growth factor （VEGF） pathway-targeted therapy for mRCC by comparing its effectiveness with that of immunotherapy. The electronic databases were searched. Randomized controlled trials （RCTs） on comparison of VEGF inhibiting drugs （sorafenib, sunitinib and bevacizumab） with interferon （IFN） or placebo for mRCC treatment were included. Data were pooled to meta-analyze. A total of 7 RCTs with 3451 patients were involved. The results showed that anti-VEGF agents improved progression-free survival （PFS） and offered substantial clinical benefits to patients with mRCC. Among them, sunitinib had a higher overall response rate （ORR） than IFN （47% versus 12%, P〈0.000001）. Bevacizumab plus IFN produced a superior PFS [risk ratio （RR）： 0.86, 95% confidence interval （CI）： 0.76-0.97; P=0.01] and ORR （RR： 2.19; 95% CI： 1.72-2.78; P〈0.00001） in patients with mRCC over IFN, but it yielded an increase by 31% in the risk of serious toxic effects （RR： 1.31; 95% CI 1.20-1.43; P〈0.00001） as compared with IFN. The overall survival （OS） was extended by sorafenib （17.8 months） and sunitinib （26.4 months） as compared with IFN （13 months）. It was concluded that compared with IFN therapy, VEGF pathway-targeted therapies improved PFS and achieved significant therapeutic benefits in mRCC. However, the risk to benefit ratio of these agents needs to be further evaluated.
